Trials / Recruiting
RecruitingNCT05799326
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Yi Yang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of levofloxacin in treating acute ischemic stroke.
Detailed description
Acute ischemic stroke is a leading cause of disability and mortality. The investigators' previous studies suggested levofloxacin to be a newly identified neuro-protective agent, which could reduce infarct volume and improve neurologic function in animal models. To evaluate the efficacy and safety of levofloxacin in treating acute ischemic stroke patients, the prospective, multicenter and randomized controlled trial was designed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levofloxacin | Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. |
| DRUG | Levofloxacin simulant | Levofloxacin simulant is placebo. |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2023-04-05
- Last updated
- 2024-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05799326. Inclusion in this directory is not an endorsement.